Table 2.

Association of pathway activity in primary tumor with response to hormonal therapy in the patients with metastatic disease.

Pathway	Response	Low ER Activity	High ER Activity	Percentage High	Fisher Test
A. ER Pathway	CR	1	2	67%
	PR	9	6	40%
	SD > 6 m	38	31	45%	p = 0.36
	SD ≤ 6 m	5	5	50%
	PD	24	9	27%
	Non-PD	53	44	45%	OR = 0.45
	PD	24	9	27%	p = 0.10
B. PI3K Pathway	Response	Low PI3K Activity	High PI3K Activity	Percentage High	Fisher Test
	CR	3	0	0%
	PR	12	3	20%
	SD > 6 m	56	13	19%	p = 0.035
	SD ≤ 6 m	5	5	50%
	PD	19	14	42%
	CR, PR, SD > 6 m	71	16	18%	OR = 3.5
	SD ≤ 6 m, PD	24	19	44%	p = 0.003
C. TGFβ Pathway	Response	Low TGFβ Activity	High TGFβ Activity	Percentage High	Fisher Test
	CR	3	0	0%
	PR	14	1	7%
	SD > 6 m	64	5	7%	p = 0.11
	SD ≤ 6 m	10	0	0%
	PD	25	8	24%
	Non-PD	91	6	6%	OR = 4.8
	PD	25	8	24%	p = 0.008